Deerland Probiotics & Enzymes announces patent application for proprietary probiotic

The patent application (US# 2021-315808 A1) is titled “Bacillus subtilis containing composition for treatment of gastrointestinal irregularity.”

Deerland Probiotics & Enzymes (Kennesaw, GA) has announced the publication of a patent application by the U.S. Patent and Trademark Office for the probiotic species Bacillus subtilis based on compelling human clinicals performed on DE111, Deerland’s signature strain. The patent application (US# 2021-315808 A1), titled “Bacillus subtilis containing composition for treatment of gastrointestinal irregularity,” summarizes studies of 30, 60, and 90 days in individuals with bowel irregularity who consumed B. subtilis, all resulting in measurable improvements. The patent would protect the use of B. subtilis for supplements and functional foods/beverages claiming anti-fungal and anti-microbial properties that exert health benefits of gastrointestinal regularity, immune support and balancing of the microbiome.

“This use patent application underscores the safety and efficacy of B. subtilis, including DE111,” said John Deaton, PhD, vice president of science and technology at Deerland, in a press release. “And it is timely, as according to Allied Market Research, worldwide, bowel irregularity is a common occurrence in up to 32.5% of the global population; and further, bowel irregularity and the discomfort it causes increases with age.”

Corrected 1/6/21 at 11:41 AM: A previous version of this article identified the pending patent application as an issued patent, per information provided by Deerland Probiotics & Enzymes. The company has since issued a correction that is reflected in this article.